AI-Enabled Digital Stethoscope Doubles Detection of Serious Valve Disease in Primary Care Study
Key Takeaways:
- An AI-enabled digital stethoscope more than doubled the sensitivity of detecting audible valvular heart disease compared with standard auscultation in primary care.
- The technology identified twice as many previously undiagnosed cases of moderate-to-severe disease, supporting its potential role as a screening adjunct.
- Higher sensitivity came with lower specificity, raising important considerations around false positives, referral rates, and cost-effectiveness.
Overview of the study
In a recent prospective study published in the European Heart Journal Digital Health, researchers compared the diagnostic accuracy of primary care providers using conventional stethoscopes with that of a relatively novel artificial intelligence-enabled digital stethoscope. The aim was to determine whether AI-supported auscultation could improve current approaches to identifying valvular heart disease in primary care settings.
The findings showed a marked improvement in sensitivity when AI support was used. The AI system demonstrated a sensitivity of 92.3 percent for detecting audible valvular heart disease, compared with 46.2 percent for standard care (P = 0.01). Although the AI tool showed slightly lower specificity, it identified twice as many cases of previously undiagnosed moderate-to-severe disease. This pattern suggests a potential role for AI-enabled auscultation as a screening adjunct rather than a replacement for clinical judgement and assessment.
Background
Valvular heart disease is a serious cardiac condition in which one or more of the heart valves, including the aortic, mitral, tricuspid, or pulmonary valves, fail to open or close properly, disrupting normal blood flow through the heart.
People living with valvular heart disease may experience symptoms such as shortness of breath, fatigue, chest pain, and palpitations. Prevalence increases with age and is estimated to affect more than half of adults aged over 65 to some degree, although moderate-to-severe disease is considerably less common.
Diagnosis remains challenging, in part because more than half of people with clinically significant disease are asymptomatic. Traditionally, detection relies on clinician-performed cardiac auscultation. However, previous research indicates that even experienced general practitioners may have limited sensitivity when screening asymptomatic individuals, contributing to delayed diagnosis and disease progression.
Study design and methods
The study investigated whether deep learning algorithms, combined with digital acoustic recordings, could improve the detection of cardiac abnormalities that may be missed during routine examinations.
This was a prospective, single-arm diagnostic accuracy study conducted across three primary care clinics between June 2021 and May 2023. The study included 357 participants aged 50 years and older who were considered at elevated cardiovascular risk but had no prior diagnosis of valvular heart disease or a known cardiac murmur.
Risk factors included hypertension, a body mass index of 30 or higher, diabetes, hyperlipidaemia, atrial fibrillation, previous myocardial infarction, stroke or transient ischaemic attack, coronary revascularisation, or other established cardiovascular disease.
Each participant underwent two independent screening protocols:
- Standard-of-care screening: Primary care providers performed four-point cardiac auscultation using conventional stethoscopes.
- AI-augmented screening: Study coordinators recorded phonocardiogram data using a digital stethoscope. These recordings were analysed by an AI algorithm that has received clearance from the US Food and Drug Administration to detect heart murmurs.
All participants subsequently underwent echocardiography to confirm the presence or absence of structural heart disease. An independent expert panel reviewed the digital audio recordings to verify whether an audible murmur was present. This panel was blinded to the AI results.
For the purposes of the study, audible valvular heart disease was defined as moderate-to-severe disease confirmed on echocardiography together with an expert-confirmed audible murmur. This definition acknowledged that some people with structurally significant disease may not produce a clearly audible murmur.
Study findings
The AI-augmented system substantially outperformed standard auscultation in detecting audible valvular heart disease. Sensitivity was 92.3 percent with AI support compared with 46.2 percent using standard-of-care screening (P = 0.01).
Among people with confirmed disease, standard examination missed seven of thirteen cases, whereas the AI system missed only one. In terms of previously undiagnosed moderate-to-severe valvular heart disease, the AI tool identified 12 cases, compared with 6 detected by primary care providers.
This improvement in sensitivity was accompanied by reduced specificity. The AI system demonstrated a specificity of 86.9 percent, compared with 95.6 percent for clinicians using conventional auscultation (P < 0.001), resulting in a higher number of false-positive findings.
When echocardiography alone was used as the reference standard for moderate-to-severe disease, regardless of whether a murmur was audible, the AI system continued to outperform standard care. Sensitivity in this analysis was 39.7 percent for the AI system versus 13.8 percent for clinicians (P = 0.01).
Interpretation and conclusions
The findings suggest that integrating AI-enabled digital stethoscopes into primary care could substantially improve the detection of valvular heart disease compared with traditional auscultation alone. Rather than replacing clinical assessment, these tools may provide an additional layer of screening support, helping clinicians identify people who may benefit from earlier referral and further investigation.
However, improved detection does not automatically translate into better clinical outcomes. The study assessed diagnostic accuracy but did not evaluate downstream management, patient experience, or long-term prognosis.
Several authors reported affiliations with the device manufacturer, a factor that should be considered when interpreting the results, despite transparent disclosure of conflicts of interest.
The lower specificity observed with AI-augmented screening may lead to increased referrals for echocardiography and higher healthcare utilisation. This highlights the importance of future research examining cost-effectiveness, workflow impact, and optimal integration into primary care pathways.
Study limitations included a modest sample size, a limited geographic scope, incomplete demographic detail, and the absence of systematic symptom assessment. Despite these constraints, the results indicate that AI-supported auscultation may represent a meaningful advance in point-of-care cardiac screening for people at increased cardiovascular risk.
Read More